Bristol-Myers Squibb’s drive to build its Opdivo immunotherapy franchise continues, this time with a new FDA filing to treat melanoma in an earlier setting. BMS has asked the FDA for a licence to ...
Shares in Bristol-Myers Squibb were given a nudge after US regulators accepted an application to expand the use of its immunotherapy Opdivo in lung cancer. Shares in Bristol-Myers Squibb were given a ...
US regulators have accepted Bristol-Myers Squibb’s application to market its immunotherapy Opdivo plus Yervoy for the treatment of first-line advanced non-small cell lung cancer (NSCLC) in certain ...
Bristol-Myers Squibb’s drive to build its Opdivo immunotherapy franchise continues, this time with a new FDA filing to treat melanoma in an earlier setting. BMS has asked the FDA for a licence to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback